Invitation: Patient & Carer Discussion on Living with ABPA. New type of treatment.

🕙 10:00am, Thursday 12th

Get details on how to join us by clicking on the link below and choosing Thursday 12th Patients Support Meeting – you will be sent a link to the meeting via email.

https://outlook.office.com/book/[email protected]/

We are inviting people living with Allergic Bronchopulmonary Aspergillosis (ABPA), and those who care for them, to take part in an open, informal online discussion with argenx, a research-focused biotechnology company.

argenx would like to listen directly to patients and carers to better understand what day-to-day life with ABPA is really like. There is no need to prepare anything in advance — you are welcome simply to listen, or to share as much or as little as you feel comfortable.

They are particularly interested in hearing about:

• Patients’ and carers’ journeys living with ABPA

• Which symptoms are most burdensome in everyday life (for example breathlessness, cough, fatigue, thick mucus or mucus plugs)

• Where current treatments fall short from a patient or carer perspective

• What would make patients or carers feel motivated or reassured about taking part in a future clinical trial of a new ABPA therapy

The purpose of this conversation is to help researchers design future studies that reflect what matters most to patients, including which outcomes are meaningful and how trials can be made more patient-friendly.

📅 Date: Thursday 12th
🕙 Time: 10:00am
💬 Format: Open, informal discussion
📝 Preparation: None required

If you are living with ABPA, or care for someone who is, and would be interested in attending, please let us know.

A short explainer: what is ARGX-118?

argenx is developing an investigational (research-stage) treatment called ARGX-118. It is not yet a licensed medicine and is not currently available outside of research studies.

Case study

In ABPA, many people experience very thick, sticky mucus and mucus plugs that block airways and contribute to breathlessness, cough, and flare-ups. Research has shown that this mucus can sometimes contain microscopic crystals formed from proteins released by certain white blood cells involved in allergic inflammation. These crystals can make mucus denser and harder to clear.

ARGX-118 is designed to target and break down these crystals, with the aim of making mucus less thick and easier to clear from the lungs. This is a different approach from current treatments, which mainly focus on suppressing inflammation (such as steroids or biologics) or reducing fungal burden (antifungal medicines).

Because ARGX-118 is still in early development, we do not yet know how effective it will be, who might benefit most, or how it would fit alongside existing treatments. That is exactly why argenx wants to hear from patients and carers now — to understand real-world symptoms, treatment gaps, and what would genuinely matter if a future clinical trial were developed.

👉 Attending this meeting does not commit you to any trial and will not affect your care. It is simply an opportunity to share experiences and help shape future research, if you wish.